nach oben

Erschienen in:

01.11.2022 | Clinical study

Update on safety of synthetic and biological DMARDs

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Risks of cancer and major adverse cardiovascular events (MACE) are similar or reduced with biological disease-modifying antirheumatic drugs (bDMARDs) compared with conventional synthetic DMARDs (csDMARDs), and cancer and MACE are more frequent with tofacitinib than with tumour necrosis factor inhibitors (TNFi) in patients with cardiovascular risk factors. These were some of the findings of a systematic review published in Annals of Rheumatic Diseases. …

Sepriano A, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis Annals of the Rheumatic Diseases : 14 Nov 2022. Available from: URL: http://doi.org/10.1136/ard-2022-223357

Titel: Update on safety of synthetic and biological DMARDs
Publikationsdatum: 01.11.2022
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-022-28393-9

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Update on safety of synthetic and biological DMARDs

Excerpt

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2022

Multiple drugs

Antineoplastics and hydrocortisone

AZD-1222

Aspirin/warfarin

Multiple drugs

Antineoplastics